Title:
THERAPEUTIC FOR GOUT OR HYPERURICEMIA
Document Type and Number:
WIPO Patent Application WO/2020/246528
Kind Code:
A1
Abstract:
The present invention provides a pharmaceutical composition for treating or preventing gout or hyperuricemia that contains a compound represented by general formula (I) (in the formula, R1 represents a substituted or unsubstituted phenyl group, R2 represents a cyano group or a nitro group, R3 represents a hydrogen atom or a hydroxyl group, X represents an oxygen atom or -S(O)n-, n represents an integer of 0-2, and Y represents an oxygen atom or a sulfur atom) or a pharmaceutically acceptable salt thereof.
Inventors:
KOBAYASHI SHIRO (JP)
MIYAYAMA ERI (JP)
HIRANO MASUHARU (JP)
OHTA TAKASHI (JP)
MIYAYAMA ERI (JP)
HIRANO MASUHARU (JP)
OHTA TAKASHI (JP)
Application Number:
PCT/JP2020/022039
Publication Date:
December 10, 2020
Filing Date:
June 04, 2020
Export Citation:
Assignee:
NIPPON CHEMIPHAR CO (JP)
International Classes:
A61P19/06; A61K9/48; A61K31/519; A61K47/38
Domestic Patent References:
| WO2005121153A1 | 2005-12-22 | |||
| WO2019107412A1 | 2019-06-06 | |||
| WO2005121153A1 | 2005-12-22 |
Foreign References:
| JP2016520133A | 2016-07-11 | |||
| JP2019104534A | 2019-06-27 | |||
| JP2016520133A | 2016-07-11 | |||
| JP2019017439W | 2019-04-24 |
Other References:
KASHIHARA TOSHIO: "Chapter 4 Strategies for design and development of oral dosage forms", DESIGN AND EVALUATION OF ORAL DOSAGE FORMS, vol. 4, 1995, pages 47 - 67, XP009532819
WATARU KAWAKAMI: "Leading Edge Technologies for Oral Delivery of Poorly Soluble Drugs", 6 July 2016, CMC PUBLISHING, JP, ISBN: 978-4-7813-1169-2, article ONOUE SATOMI: "Chapter 3.1 Current status of drug development using amorphous technology", pages: 127 - 135, XP009532824
TANNO, FUMIE: "Evaluation of Characteristics of Hypromellose Acetate Succinate (HPMCAS) as a Carrier for Solid Dispersion -from Study to Improve In Vitro Dissolution of Poorly Water Soluble Drugs", JOURNAL OF PHARMACEUTICAL SCIENCE AND TECHNOLOGY, JAPAN, vol. 73, no. 4, 2013, pages 214 - 222, XP009520813, DOI: 10.14843/jpstj.73.214
ARTHRITIS RES THER., vol. 11, 2009, pages R46
J RHEUMATOL, vol. 31, 2004, pages 2429 - 2432
"Application Summary of Feburic (Registered Trademark) Tablet", CLINICAL PHARMACOLOGY STUDY, January 2011 (2011-01-01), pages 30
See also references of EP 3981469A4
WATARU KAWAKAMI: "Leading Edge Technologies for Oral Delivery of Poorly Soluble Drugs", 6 July 2016, CMC PUBLISHING, JP, ISBN: 978-4-7813-1169-2, article ONOUE SATOMI: "Chapter 3.1 Current status of drug development using amorphous technology", pages: 127 - 135, XP009532824
TANNO, FUMIE: "Evaluation of Characteristics of Hypromellose Acetate Succinate (HPMCAS) as a Carrier for Solid Dispersion -from Study to Improve In Vitro Dissolution of Poorly Water Soluble Drugs", JOURNAL OF PHARMACEUTICAL SCIENCE AND TECHNOLOGY, JAPAN, vol. 73, no. 4, 2013, pages 214 - 222, XP009520813, DOI: 10.14843/jpstj.73.214
ARTHRITIS RES THER., vol. 11, 2009, pages R46
J RHEUMATOL, vol. 31, 2004, pages 2429 - 2432
"Application Summary of Feburic (Registered Trademark) Tablet", CLINICAL PHARMACOLOGY STUDY, January 2011 (2011-01-01), pages 30
See also references of EP 3981469A4
Attorney, Agent or Firm:
TANAI Sumio et al. (JP)
Download PDF: